Compare Stocks

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EPIX ESSA Pharma	$6.68 -0.6%	$8.68	$2.56 ▼ $11.67	$295.52M	1.62	137,689 shs	75,009 shs
FWP Forward Pharma A/S	$1.95	$2.17	$1.50 ▼ $6.48	$13.83M	1.38	7,484 shs	N/A
MBRX Moleculin Biotech	$4.59 +1.5%	$7.07	$4.28 ▼ $15.75	$10.24M	1.95	30,532 shs	7,747 shs
TLSA Tiziana Life Sciences	$0.67 +4.7%	$0.49	$0.41 ▼ $1.27	N/A	0.82	94,882 shs	583,681 shs
UMRX Cogent Biosciences	$6.61 +1.2%	$10.50	$0.29 ▼ $3.72	$280.72M	3.93	1.22 million shs	1.06 million shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EPIX ESSA Pharma	-4.95%	-18.55%	-27.74%	-23.46%	+136.62%
FWP Forward Pharma A/S	0.00%	0.00%	0.00%	0.00%	0.00%
MBRX Moleculin Biotech	+6.07%	-5.02%	-42.22%	-44.66%	-62.17%
TLSA Tiziana Life Sciences	+24.76%	+40.76%	+30.61%	+9.74%	-45.30%
UMRX Cogent Biosciences	+1.23%	+0.92%	-1.93%	+43.38%	-40.45%

Strange new buyer driving up gold (Ad)

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EPIX ESSA Pharma	2.8479 of 5 stars	3.5	4.0	0.0	0.0	2.8	3.3	0.0
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	2.2833 of 5 stars	3.5	3.0	0.0	0.0	2.9	0.0	1.3
TLSA Tiziana Life Sciences	0.4686 of 5 stars	0.0	3.0	0.0	0.0	2.5	1.7	0.6
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EPIX ESSA Pharma	3.00	Buy	$16.50	147.01% Upside
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	3.00	Buy	$35.00	662.53% Upside
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest UMRX, FWP, TLSA, EPIX, and MBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/12/2024	MBRX Moleculin Biotech	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
3/26/2024	MBRX Moleculin Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $20.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$3.30 per share	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	$10.09 per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$11.70 per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.19 per share	N/A
UMRX Cogent Biosciences	$22.50M	12.48	N/A	N/A	$1.04 per share	6.36

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EPIX ESSA Pharma	-$26.58M	-$0.59	N/A	N/A	N/A	N/A	-17.41%	-17.04%	5/14/2024 (Estimated)
FWP Forward Pharma A/S	-$1.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	-$29.77M	-$13.64	N/A	N/A	N/A	N/A	-80.91%	-67.69%	5/9/2024 (Estimated)
TLSA Tiziana Life Sciences	-$15.40M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	4/24/2024 (Estimated)
UMRX Cogent Biosciences	-$31.83M	-$1.04	N/A	N/A	N/A	-96.84%	-87.78%	-52.14%	N/A

Latest UMRX, FWP, TLSA, EPIX, and MBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/13/2024	12/31/2023	EPIX ESSA Pharma	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
FWP Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A
UMRX Cogent Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EPIX ESSA Pharma	N/A	40.74	40.74
FWP Forward Pharma A/S	N/A	18.43	N/A
MBRX Moleculin Biotech	N/A	3.86	3.86
TLSA Tiziana Life Sciences	N/A	N/A	N/A
UMRX Cogent Biosciences	0.18	2.90	2.90

Ownership

Institutional Ownership

Company	Institutional Ownership
EPIX ESSA Pharma	75.12%
FWP Forward Pharma A/S	12.57%
MBRX Moleculin Biotech	15.52%
TLSA Tiziana Life Sciences	N/A
UMRX Cogent Biosciences	26.39%

Insider Ownership

Company	Insider Ownership
EPIX ESSA Pharma	14.70%
FWP Forward Pharma A/S	71.47%
MBRX Moleculin Biotech	6.70%
TLSA Tiziana Life Sciences	39.82%
UMRX Cogent Biosciences	31.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
EPIX ESSA Pharma	50	44.24 million	37.74 million	Optionable
FWP Forward Pharma A/S	4	7.09 million	2.02 million	Not Optionable
MBRX Moleculin Biotech	18	2.23 million	2.08 million	Not Optionable
TLSA Tiziana Life Sciences	9	N/A	N/A	Optionable
UMRX Cogent Biosciences	72	42.47 million	N/A	Not Optionable

UMRX, FWP, TLSA, EPIX, and MBRX Headlines

Source	Headline
	Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT) markets.businessinsider.com - February 26 at 5:33 PM
	Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA) markets.businessinsider.com - February 26 at 8:53 AM
	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results markets.businessinsider.com - February 26 at 8:53 AM
	Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential markets.businessinsider.com - February 15 at 8:43 AM
	Cogent Biosciences Stock Soars After $225M Private Placement marketwatch.com - February 14 at 10:02 AM
	Cogent Biosciences announces oversubscribed $225M private placement msn.com - February 14 at 10:02 AM
	Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects markets.businessinsider.com - February 9 at 2:23 AM
	Citi starts Cogent Biosciences at buy, cites GI tumor drug potential msn.com - February 8 at 4:22 PM
	Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial markets.businessinsider.com - December 15 at 7:55 PM
	Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib markets.businessinsider.com - December 13 at 5:33 PM
	Dow Surges 100 Points; Cogent Biosciences Shares Plunge markets.businessinsider.com - December 11 at 12:21 PM
	Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment markets.businessinsider.com - December 11 at 12:21 PM
	Cogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosis markets.businessinsider.com - December 11 at 10:08 AM
	Cogent slumps after mid-stage data for rare disorder therapy msn.com - December 11 at 10:08 AM
	Potential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Shares markets.businessinsider.com - November 21 at 9:11 AM
	Promising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciences markets.businessinsider.com - November 14 at 8:40 AM
	Promising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciences markets.businessinsider.com - November 4 at 5:21 PM
	Promising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Rating markets.businessinsider.com - October 28 at 7:55 AM
	Analyst Expectations for Cogent Biosciences's Future benzinga.com - August 30 at 8:53 AM
	Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor msn.com - August 15 at 5:40 PM
	LifeSci Capital Remains a Buy on Cogent Biosciences (COGT) markets.businessinsider.com - August 8 at 3:59 PM
	Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect? msn.com - July 11 at 1:47 PM
	Cogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisition marketwatch.com - June 13 at 11:04 PM
	9 Analysts Have This to Say About Cogent Biosciences markets.businessinsider.com - June 12 at 4:10 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ESSA Pharma

NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Forward Pharma A/S

NASDAQ:FWP

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

Moleculin Biotech

NASDAQ:MBRX

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Tiziana Life Sciences

NASDAQ:TLSA

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Cogent Biosciences

NASDAQ:UMRX

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial